RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 22.20
-0.25 (-1.11%)
Aug 19, 2026, 11:32 AM CST
RBC Bioscience Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 220.6 | 219.71 | 205.25 | 172.47 | 173.89 | 251.18 | |
Revenue Growth | 9.29% | 7.05% | 19.00% | -0.82% | -30.77% | -56.33% |
Cost of Revenue | 119.01 | 118.25 | 107.17 | 99.57 | 100.89 | 134.11 |
Gross Profit | 101.6 | 101.46 | 98.07 | 72.9 | 73.01 | 117.07 |
Selling, General & Admin | 49.38 | 49.02 | 52.42 | 47.41 | 49.61 | 52.44 |
Research & Development | 25.36 | 17.33 | 9.86 | 10.84 | 15.74 | 16.39 |
Operating Expenses | 74.83 | 66.43 | 62.69 | 58.36 | 65.26 | 68.46 |
Operating Income | 26.77 | 35.03 | 35.38 | 14.54 | 7.75 | 48.61 |
Interest Expense | -9.16 | -9.69 | -10.31 | -10 | -7.57 | -6.33 |
Interest & Investment Income | 0.32 | 0.4 | 0.5 | 0.36 | 0.16 | 0.17 |
Other Non Operating Income (Expenses) | 8.53 | 4.06 | 2.88 | 3 | 4.57 | -5.98 |
EBT Excluding Unusual Items | 26.45 | 29.8 | 28.45 | 7.89 | 4.91 | 36.48 |
Gain (Loss) on Sale of Assets | - | - | 0 | -0.02 | 0.01 | -0.54 |
Legal Settlements | - | - | -1.49 | - | - | - |
Other Unusual Items | - | - | - | - | - | 0.01 |
Pretax Income | 26.45 | 29.8 | 26.96 | 7.87 | 4.92 | 35.95 |
Income Tax Expense | 5.4 | 6.25 | 5.4 | 1.44 | 1.14 | 7.22 |
Net Income | 21.06 | 23.54 | 21.57 | 6.43 | 3.78 | 28.73 |
Net Income to Common | 21.06 | 23.54 | 21.57 | 6.43 | 3.78 | 28.73 |
Net Income Growth | 7.49% | 9.17% | 235.40% | 70.20% | -86.85% | -79.75% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 13 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 14 |
Shares Change | -0.04% | 0.18% | 0.37% | -0.08% | 5.81% | 2.28% |
EPS (Basic) | 1.48 | 1.65 | 1.51 | 0.45 | 0.26 | 2.21 |
EPS (Diluted) | 1.47 | 1.64 | 1.50 | 0.45 | 0.26 | 2.13 |
EPS Growth | 8.05% | 9.33% | 236.70% | 69.01% | -87.61% | -80.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 41.95 | 34.08 | 53.8 | 8.21 | -3.36 | -475.02 |
Free Cash Flow Per Share | 2.92 | 2.37 | 3.75 | 0.57 | -0.23 | -35.11 |
Dividend Per Share | 1.500 | 1.500 | 0.560 | 0.400 | 1.018 | 0.827 |
Dividend Growth | 2846.96% | 167.86% | 40.00% | -60.71% | 23.19% | -82.05% |
Gross Margin | 46.05% | 46.18% | 47.78% | 42.27% | 41.98% | 46.61% |
Operating Margin | 12.13% | 15.94% | 17.24% | 8.43% | 4.46% | 19.35% |
Profit Margin | 9.55% | 10.72% | 10.51% | 3.73% | 2.17% | 11.44% |
Free Cash Flow Margin | 19.01% | 15.51% | 26.21% | 4.76% | -1.93% | -189.12% |
EBITDA | 41.4 | 49.27 | 51.6 | 31.86 | 25.04 | 61.47 |
EBITDA Margin | 18.77% | 22.43% | 25.14% | 18.47% | 14.40% | 24.47% |
D&A For EBITDA | 14.63 | 14.25 | 16.22 | 17.32 | 17.29 | 12.86 |
EBIT | 26.77 | 35.03 | 35.38 | 14.54 | 7.75 | 48.61 |
EBIT Margin | 12.13% | 15.94% | 17.24% | 8.43% | 4.46% | 19.35% |
Effective Tax Rate | 20.39% | 20.99% | 20.01% | 18.33% | 23.15% | 20.08% |